Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process

Mishiro, Shunji; Hoshi, Yuji; Yoshikawa, Akira; Gotanda, Tohru; Tsuda, Fumio; Takeda, Kohsuke; Akahane, Yoshihiro; Takahashi, Kazuaki; Yamada, Hiroshi; Okamoto, Hiroaki; Peterson, David A.; Muchmore, Elizabeth

doi:10.1016/0140-6736(90)93101-t

Cited by 221 publications

(76 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consistent with results from previous studies, 10,28,31,32,33 we found that the prevalence of autoantibodies in HCV patients was significantly higher than those in uninfected controls. Our study showed a high prevalence of ASMA, ANA and RF.…”

Section: Discussionsupporting

confidence: 92%

“…15,21,24,25,26 The mechanisms by which viruses in general, and HCV in particular, trigger or enhance autoimmunity can be explained in various ways. 27,28,29,30 According to one theory, viruses may non-specifically trigger immune regulatory cells, such as lymphocytes or macrophages, inducing them to react with self-antigens in multiple organs, and therefore cause tissue injury as well as extrahepatic diseases. Another theory suggests that viruses alter the antigenic profile of infected cells (such as hepatocytes) by changing, releasing or exposing selfantigens that are usually "hidden" and for which the immune system usually has no tolerance.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of Autoantibodies in Patients with Hepatitis C Virus Infection in Oman

Alnaqdy¹,

Alfahdi²,

Al-Kobaisi³

et al. 2003

Ann Saudi Med

View full text Add to dashboard Cite

Background: HCV genotype patterns and HLA types in the Omani population may be unique. Subjects and Methods: Tests for 12 different autoantibodies were carried out on 50 HCV-infected patients and on 27 HCV-seronegative controls. An immunoassay for the detection of anti-HCV antibodies was performed on patient and control sera. HCV PCR was carried out on those sera which were positive for HCV antibodies. Results: All patients' sera were positive for HCV antibodies and all control sera were negative. Sixty-six percent of patients were positive for at least one autoantibody. In contrast, only 33% of the controls showed positivity for one or more autoantibodies. Conclusion: This study found a significant difference in the prevalence of autoantibodies between patients and controls, and between organ-and non-organ specific autoantibodies among the patients. A comparison with autoantibody patterns reported for HCV-infected patients in other parts of the world suggest that patterns in HCVinfected individuals in the Omani population are unique.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Prevalence of Autoantibodies in Patients with Hepatitis C Virus Infection in Oman

Alnaqdy¹,

Alfahdi²,

Al-Kobaisi³

et al. 2003

Ann Saudi Med

View full text Add to dashboard Cite

show abstract

“…In cases of community-acquired infection, 62% develop chronic hepatitis in the USA [5]. Recent data show evidence for the presence of several autoimmune phenomena in patients with HCV infection, such as oligo-or polyarthritis [6,7], primary Sjogren's syndrome [8,9], membranoprolifcrative glomerulonephritis [10], cryoglobulinaemia [11][12][13][14], antinuclear, anti-mitochondrial, and anti-smooth muscle antibodies [11], rheumatoid factors [11,13], autoantibodies targeting a host protein named GOR, cloned from a chimpanzee infected with non-A, non-B hepatitis [15,16], and LKM-1 antibodies in adult palients with concomitant type 2 autoimmune hepatitis [17][18][19][20][21]. Some of the events were related to interferon-alpha {lFN-«) treatment [22] or to concomitant HCV infection due to exposure to human blood products [23].…”

Section: Introductionmentioning

confidence: 99%

Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases

Mühlen

Chan

Peebles

et al. 1995

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYThree patients with hepatitis C virus (HCV)-related chronic liver disease were shown to have autoantibodies strongly reacting with cytoskeletal fibres of non-muscle cells. The heavy chain of non-muscle myosin microfilament was the main target for those autoantibodies. as determined by (i) cell and tissue immunofluorescence studies showing colocalization with an anti-myosin antibody prototype; (ii) primary reactivity in immunoblotting with a 200-kD protein, using either MOLT-4 cells, human platelets, or affinity-purified non-muscle myosin as antigen extract; and (iii) immunoblotting of similar Immunoreactive fragments in papain-digested MOLT-4 cell extracts, by using those human sera and antibody prototype. Autoantibodies to non-muscle myosin heavy chain were not previously reported in patients with chronic liver diseases, especially in those associated with HCV infection.

show abstract

“…2 The high HCV mutation rate readily generates variants that contribute to establishing the persistent infection. 3 HCV is known to cause a variety of systemic immunologic reactions or abnormalities such as circulating immune complexes, 4 autoantibodies, 5,6 and autoimmune manifestations. [7][8][9][10] Although the liver is considered the primary site of HCV replication with convincing evidence, 11,12 systemic or extrahepetic immune reactions, as well as intrahepatic responses, can be induced in the course of chronic infection.…”

mentioning

confidence: 99%

Functional B-cell response in intrahepatic lymphoid follicles in chronic hepatitis C

et al. 1999

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is recognized as a major causative agent of parenterally transmittable non-A, non-B hepatitis. 1 HCV infection often persists for a long time and leads to chronic liver diseases; at least half of the HCV cases develop into chronic hepatitis, and 10% to 20% of cases develop into cirrhosis. 2 The high HCV mutation rate readily generates variants that contribute to establishing the persistent infection. 3

show abstract

Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process

Cited by 221 publications

References 15 publications

Prevalence of Autoantibodies in Patients with Hepatitis C Virus Infection in Oman

Prevalence of Autoantibodies in Patients with Hepatitis C Virus Infection in Oman

Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases

Functional B-cell response in intrahepatic lymphoid follicles in chronic hepatitis C

Contact Info

Product

Resources

About